论文部分内容阅读
目的探讨左卡尼汀治疗新生儿窒息后心肌损伤的临床疗效。方法选取黄冈市妇幼保健院2013年1月—2015年1月收治的新生儿窒息后心肌受损患儿85例,随机分为常规治疗组42例与左卡尼汀组43例。常规治疗组患儿予以常规治疗,左卡尼汀组在常规治疗组治疗基础上予以左卡尼汀治疗,两组患儿均连续治疗10 d。比较两组新生儿窒息后受损心肌恢复率、治疗前后心肌酶谱指标[肌酸激酶同工酶(CK-MB)、天冬氨酸转氨酶(AST)、肌酸激酶(CK)、肌钙蛋白T(Tn T)]及不良反应发生情况。结果左卡尼汀组患儿受损心肌恢复率高于常规治疗组(P<0.05)。治疗前,两组患儿CK-MB、AST、CK及Tn T水平比较,差异无统计学意义(P>0.05);治疗后左卡尼汀组CK-MB、AST、CK及Tn T水平低于常规治疗组(P<0.05)。两组患儿不良反应发生率比较,差异无统计学意义(P>0.05)。结论左卡尼汀治疗新生儿窒息后心肌损伤的临床疗效确切,可有效修复患儿的受损心肌,改善心肌酶谱指标,且安全性高。
Objective To investigate the clinical efficacy of levocarnitine in the treatment of neonatal asphyxia myocardial injury. Methods Eighty-five children with myocardial damage after neonatal asphyxia were randomly divided into routine treatment group (n = 42) and levocarnitine group (n = 43), from March 2013 to January 2015 in Huanggang Maternal and Child Health Hospital. The patients in the conventional treatment group were treated routinely, and the levocarnitine group was treated with levocarnitine on the basis of the conventional treatment group. Both groups were treated continuously for 10 days. The myocardial recovery rate of neonatal asphyxia was compared between the two groups before and after treatment. The levels of myocardial enzymes (CK-MB, AST, creatine kinase (CK), muscle calcium Protein T (Tn T)] and adverse reactions. Results The recovery rate of myocardial damage in L-carnitine group was higher than that in routine treatment group (P <0.05). Before treatment, the levels of CK-MB, AST, CK and Tn T were not significantly different between the two groups (P> 0.05). The levels of CK-MB, AST, CK and Tn T In the conventional treatment group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Locardin treatment of neonatal asphyxia myocardium injury clinical efficacy is exact, can effectively repair children with impaired myocardium, myocardial enzymes improve myocardial indicators, and high safety.